Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women
Brief Summary: A new approach to HIV prevention currently being studied includes the use of microbicides, substances that kill microbes. Tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) are oral, FDA-approved, anti-HIV drugs, and tenofovir gel is an experimental microbicide. The purpose of this study is to determine the safety and effectiveness of daily tenofovir 1% gel compared to a vaginal placebo gel, and the safety and effectiveness of oral TDF and oral FTC/TDF compared to an oral placebo in preventing HIV infection among women at risk for sexually transmitted infections.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate placebo, Drug: Tenofovir disoproxil fumarate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate, Drug: Tenofovir disoproxil fumarate placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate placebo, Drug: Tenofovir disoproxil fumarate placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir 1% vaginal gel | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir placebo | Intervention Type: DRUG; Name: Emtricitabine/tenofovir disoproxil fumarate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Emtricitabine/tenofovir disoproxil fumarate placebo; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Tenofovir disoproxil fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Tenofovir disoproxil fumarate placebo; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Tenofovir 1% vaginal gel; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Tenofovir placebo; Assigned to Arm(s): 5
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Acidform Lubricant | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: HEC gel | Intervention Type: DRUG; Name: Acidform Lubricant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: HEC gel; Assigned to Arm(s): 2
C: Arm Label: Tenofovir 1% vaginal gel; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir gel | Arm Label: Universal placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Universal placebo gel | Intervention Type: DRUG; Name: Tenofovir gel; Assigned to Arm(s): Tenofovir 1% vaginal gel | Intervention Type: DRUG; Name: Universal placebo gel; Assigned to Arm(s): Universal placebo gel
D: Arm Label: Placebo Vaginal Ring; Type: PLACEBO_COMPARATOR; Interventions: Combination Product: Placebo Vaginal Ring | Arm Label: Dapivirine Vaginal Ring; Type: EXPERIMENTAL; Interventions: Combination Product: Dapivirine Vaginal Ring, 25 mg | Intervention Type: COMBINATION_PRODUCT; Name: Placebo Vaginal Ring; Assigned to Arm(s): Placebo Vaginal Ring | Intervention Type: COMBINATION_PRODUCT; Name: Dapivirine Vaginal Ring, 25 mg; Assigned to Arm(s): Dapivirine Vaginal Ring

Answer: A